Related Experiment Video
Updated: May 3, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Robotic technology for pelvic exenteration in cases of cervical cancer
Christos Iavazzo1, Ioannis D Gkegkes2
1IASO Maternity Hospital, Athens, Greece.
Background:
Cervical cancer represents one of the most common types of neoplasia among women; the use of minimally invasive techniques in the treatment of cervical cancer is a challenge.
Objectives:
To present evidence regarding robotic technology in the performance of pelvic exenteration in cases of cervical cancer.
Search Strategy:
PubMed and Scopus databases were searched.
Selection Criteria:
Articles examining the use of robotic technology for pelvic exenteration in cases of cervical cancer were included.
Data Collection And Analysis:
Four studies were included.
Main Results:
Most cancers treated with robotic-assisted pelvic exenteration were squamous cell carcinomas of the cervix. The stage of primary cancer ranged from IB2 to IVA. In 7 of the 8 patients, anterior pelvic exenteration was performed; the other patient underwent total pelvic exenteration. Procedure duration ranged from 375 to 600 minutes; blood loss was 200-550 mL. Postoperative complications occurred in 2 of the 8 patients and included perineal abscess, Miami pouch fistula, and ureteral stenosis. Postoperative hospital stay ranged from 3 to 53 days, and postoperative follow-up ranged from 2 to 31 months.
Conclusions:
The gold standard for pelvic exenteration remains the open surgical approach; however, the application of robotic technology could be an alternate choice associated with excellent results.
